Category: CannabisNewsWire Release

Software Effective Solutions Corp. (SFWJ) Subsidiary Looks to Ride Expansion Trend, Moving into Central American Cannabis Markets

  • The global textile industry is increasingly turning to hemp, celebrating the plant’s ability to enhance soil health, support biodiversity, suppress weeds, and increase yields
  • Central American expansion is part of MedCana’s broader strategy to strengthen its presence in the global cannabis and agricultural technology sectors 
  • MedCana is a pioneer in the integration of technology and agriculture, focusing on cannabis and emerging technologies

Worldwide, more farmers are opting to grow hemp because of its agricultural benefits. Leveraging that trend, Eko2o Environmental Solutions S.A.S., a majority-owned subsidiary of Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ), is expanding operations into Costa Rica and the broader Central American market (https://cnw.fm/RCohp). As the company moves forward with expansion plans, Eko2o provides invaluable insight and expertise gained from being at the forefront of agricultural innovation and offering cutting-edge solutions that enhance efficiency and sustainability in farming practices.

“Since its recent legalization in countries around the world, the global textile industry is increasingly turning to hemp, celebrating the plant’s ability to enhance soil health, support biodiversity, suppress weeds, and increase yields among subsequent crops — all while relying on little or no inputs,” stated a recent article (https://cnw.fm/xz9U5). “Fiber hemp holds strong sustainability potential, but as it gains popularity, it is vital that we look at how it is grown.

“This means taking on board lessons learned from other fiber crops, where heavy synthetic pesticide and fertilizer use have become the norm,” the article continued. “At this early stage, the industry has a unique opportunity to shape fiber hemp standards from the soil up, setting up systems that maximize measurable benefits for the climate, ecosystems, and communities.”

Factors contributing to the company’s decision to expand into these key markets are the region’s rich biodiversity, its progressive environmental policies, and a growing demand for sustainable agricultural practices. Eko2o’s strategic expansion plans include establishing partnerships with local organizations, setting up operations that will serve as centers for research and development, and introducing its state-of-the-art agricultural technology solutions to the market.

“Costa Rica and Central America are regions known for their commitment to environmental sustainability and high agricultural potential,” said Eko2o CEO Juan Ricardo Velez. “This makes them the perfect match for Eko2o’s mission and expertise. We are excited about the opportunity to collaborate with local farmers and businesses to promote sustainable agriculture that benefits both the economy and the ecosystem.”

This expansion is part of MedCana’s broader strategy to strengthen its presence in the global cannabis and agricultural technology sectors. Recently, the company has inked several key deals and completed strategic acquisitions that have positioned the company as a key player in the industry. As a MedCana subsidiary, Eko2o has established a reputation for offering state-of-the-art greenhouse infrastructure and agricultural technology solutions. The company is committed to enhancing the efficiency and sustainability of agricultural production in Colombia and beyond.

Operating under Software Effective Solutions Corp., MedCana is a pioneer in the integration of technology and agriculture, focusing on cannabis and emerging technologies. With a vision to revolutionize the industry through innovation, MedCana is dedicated to acquiring and partnering with companies that align with its mission of promoting sustainable and technologically advanced agricultural practices.

MedCana is committed to developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. These recent acquisitions reflect the company’s focus on scientific advancements and sustainable practices as it works to achieve the broader goal of leading the cannabis industry through strategic growth and pioneering research. The company is excited about the future prospects these new assets bring to its operations and the vast opportunities for innovation they unlock.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://cnw.fm/SFWJ

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

More Than Just Green: Zoned Properties Inc. (ZDPY) Experts in Complexities of Opening a Cannabis Dispensary

  • With cannabis legalization exploding nationwide, there are now over 19,500 incorporated U.S. cities, town, and villages that will govern local cannabis regulations
  • Zoned Properties is comprised of a team of experts in cannabis zoning codes utilizing proprietary technology to identify premium cannabis dispensary locations
  • Focused on its dispensary landlord model, the company has listed its largest cultivation property in Arizona for sale for $16 million

The cannabis industry is flourishing, but opening a dispensary isn’t a walk in the park. Aspiring entrepreneurs face a maze of regulations and considerations beyond simply having a quality supply chain.

Unprecedented Geographic Growth

California sparked the green wave in 1996 by becoming the first state to legalize medical marijuana. Fast forward 16 years, and Colorado and Washington shattered another barrier in 2012, allowing recreational cannabis use. Since then, the domino effect has been undeniable, with 38 states now permitting medical marijuana and 24 embracing recreational use.

In 2010, public approval for legal cannabis was just 32%. Today, with industry sales nearing $40 billion annually, approval is 91%. With that, there are now over 19,500 incorporated U.S. cities, town, and villages that will govern local cannabis regulations.

Zoning Laws and Location

Unlike many businesses, cannabis dispensaries are heavily restricted by state and local zoning ordinances. Understanding these complex regulations is crucial. Some areas completely ban dispensaries, while others have strict limitations on location. Navigating these restrictions can be a minefield, requiring expertise in real estate and community planning codes.

Not long after Colorado and Washington made history, Zoned Properties (OTCQB: ZDPY) was formed for the purpose of capitalizing on the real estate component of the burgeoning cannabis market. The company assembled a team of real estate experts specialized in different market nuances and undergirded their experience by developing a cutting-edge technology that differentiates Zoned Properties from anyone else in the industry.

The history and future of the company is brilliantly summarized in a recent Bell2Bell podcast with Zoned Properties CEO and Chairman Bryan McLaren.

Knowing Your Market

Finding the right location goes beyond zoning. Just because marijuana is legal doesn’t mean there’s specific demand. Demographics, traffic patterns, and competitor saturation all influence success. Data analysis and market research are crucial to ensure a dispensary caters to a viable customer base.

Zoned Properties’ proprietary technology plots every parcel of land in every legal cannabis state to know the codes and zoning at every location. Furthermore, the system identifies areas of high consumer demand and low supply. In other words, a perfect location for a dispensary.

Zoned Properties doesn’t just find properties; they transform them. Their team of real estate and community planning experts navigate the complex world of zoning regulations to obtain “special use”, or “conditional use” permits necessary for properties to operate as cannabis dispensaries. This entitlement significantly increases a property’s value.

The Cannabis Friendly Landlord

The business model has changed some over the years, with ZDPY management identifying the best way to build value is through owning and renting dispensaries via long-term absolute-net lease agreements. To that end, the company intends to fill its coffers by positioning to sell its largest cultivation property in Chino Valley, Arizona, which it recently listed for $16 million.

In its March 2024 corporate presentation, Zoned Properties said it had $3.1 million in cash on hand. Add in another $16 million and that is an anomaly of cash for a company with a market capitalization around only $7 million.

The dilution-free capital from the sale will be deployed to continue aggressive dispensary expansion into states exploding with growth and demand, including Ohio and Illinois.

For more information, visit the company’s website at www.ZonedProperties.com.

NOTE TO INVESTORS: The latest news and updates relating to ZDPY are available in the company’s newsroom at https://cnw.fm/ZDPY

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Germany May Initiate Legal Adult-Use Cannabis Sales Via Regulations, Bypassing Standalone Law

Germany is progressing with the next stage of cannabis legalization by initiating a pilot program for commercial sales using an administrative process instead of waiting for legislators to pass a separate measure as initially anticipated. It has long been expected that lawmakers would introduce and approve additional sales bills to complete the second phase of legalization. However, the government is opting for a rulemaking approach, potentially expediting the implementation process.

Cannabis legalization was set in motion under a measure led by Germany’s Ministry of Health, which went into force in April 2024. This allows adults to use and grow marijuana and join clubs for access to the plant, with cooperative launches expected in July. Nonetheless, there is currently no established commercial sales road map.

According to a report from Tagesspiegel Background, the existing law provides regulatory flexibility to build upon the original reform. Germany’s Ministry of Agriculture has the authority to create regulations for a commercial pilot initiative, enabling adults to purchase marijuana in specific areas without requiring further legislative action.

However, this approach also raises the possibility of easier reversal by a future government. Nevertheless, in the short-term, expediting the sales process is possible. According to reports, representatives from the Agricultural Ministry have sent out a letter asking for comments by May 10, 2024, on possible rules on retail sales under a pilot initiative.

Karl Lauterbach, Germany’s health minister, who has been leading the government’s marijuana legalization efforts, mentioned to Bundestag members last year that the commercial sales program is under consideration. With legalization already in place, there is growing pressure to accelerate this process.

Previously, the Bundesrat representing different states attempted to block the legalization proposal enacted last September, but this effort failed. Bundesrat members later worked with Lauterbach and other government officials to find a compromise.

The first legalization framework was accepted by Germany’s cabinet in late 2022, but to uphold its international responsibilities, the government sought approval from the European Union. Hearings were held in 2022 to provide legislation that would remove the prohibition.

In November 2023, government representatives from various countries, including the United States, convened in Germany to discuss international cannabis policy as the host country pursued legalization.

A delegation of German legislators visited the United States in 2022, touring marijuana businesses in California to inform Germany’s approach to legalization. The visit followed a groundbreaking meeting between Netherlands, Germany, Malta and Luxembourg officials to discuss plans and obstacles related to recreational cannabis legalization.

The coalition government leaders revealed some details of their agreement to legalize cannabis in 2021 and declared that they had come to an agreement to eliminate prohibition.

Meanwhile, the drug control arm of the United Nations recently restated its stance that legalizing cannabis for nonscientific or nonmedical purposes violates international treaties. However, it acknowledged Germany’s government for scaling back its marijuana plans before the upcoming vote.

This expedited way to get adult-use cannabis sales underway is likely to be applauded by the wider marijuana industry, including major companies such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF), because as it would facilitate access to recreational marijuana for Germans who are interested in consuming the substance.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners with the National Research Council of Canada for DehydraTECH-GLP-1 Mode of Action Investigation

  • Lexaria, a global innovator in drug delivery platforms, just announced its newest relationship with the National Research Council of Canada (“NRC”)
  • Specific molecular characteristics of the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, processed with Lexaria’s patented DehydraTECH(TM) technology, will be evaluated
  • Previous research has shown that using a DehydraTECH-semaglutide capsule composition yields a 43% higher peak level of semaglutide in blood compared to Rybelsus(R). This has potential for increased weight-loss and diabetic control
  • Lexaria’s management is confident that this partnership will complement the company’s animal and human pharmacokinetic and pharmacodynamic studies for the 2024 calendar year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced a partnership with the National Research Council of Canada (“NRC”) that will pursue an applied research program to evaluate specific molecular characteristics of the company’s patented DehydraTECH(TM) technology processed with glucagon-peptide 1 (“GLP-1”) drug, semaglutide, related to its mode of action and performance (https://cnw.fm/tFjNC).

The work program will utilize simulated gastric fluid, mimicking conditions in the human gut. In addition, various testing methods will be employed, among them size exclusion chromatography (“SEC”), polyacrylamide gel electrophoresis (“PAGE”), dynamic light scattering (“DLS”), and matrix-assisted laser desorption ionization mass spectrometry (“MALDI MS”).

GLP-1 drugs have shown significant benefits in weight management and addressing diabetes. Previous research has shown that using a DehydraTECH-semaglutide capsule composition yields a 43% higher peak level of semaglutide in blood than an unprocessed Rybelsus(R) tablet. The benefits also extend to doing away with painful injections, which are the norm with GLP-1 delivery.

Lexaria’s management believes this partnership could help fast-track the company’s push for the adoption of DehydraTECH with GLP-1 drugs. It will also be integral in showcasing the potential of the technology while inching the company closer to tapping into an industry projected to be valued at $133.5 billion by 2030 (https://cnw.fm/GjFj1).

“We are excited about our partnership with the NRC for the mode of action molecular characterization of DehydraTECH-GLP-1 drugs. This work program could potentially provide data to assist Lexaria’s efforts in partnering with the pharmaceutical industry for the most rapid introduction possible of DehydraTECH with GLP-1 drugs,” noted John Docherty, Lexaria’s president.

This partnership follows Lexaria’s resolve to double down on GLP-1 studies for the 2024 calendar year. It also follows the recent independent third-party ethics review board approval for its GLP-1 human pilot study #2, which seeks to explore the oral delivery of GLP-1 drugs. In addition, in March Lexaria announced details of its WEIGHT-A24-1 animal study which will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination (https://cnw.fm/Qdt0X).

Lexaria’s management is confident that by identifying the molecular behavior of DehydraTECH-processed pure semaglutide compositions, the findings will complement the company’s animal and human pharmacokinetic and pharmacodynamic studies for the 2024 calendar year. In addition, it is hopeful that this could ultimately lead to alternative formulations with enhanced performance. The program is expected to be completed in early August, with results reported as soon as possible after that.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – CannaCon Names CannabisNewsWire, IBN as Media Partners for Upcoming 2024 Events

CannaCon, a global business-to-business (“B2B”) venue for cannabis businesses, marijuana entrepreneurs, investors and community partners, has selected CannabisNewsWire (“CNW”), a specialized communications platform for the cannabis sector and one of more than 60 brands powered by IBN, as the Official NewsWire for its upcoming CannaCon West Albuquerque; the event is slated for May 17–18, 2024. In addition, CannabisNewsWire and IBN will partner with CannaCon as official media partners for several upcoming events, including Midwest conferences scheduled on Aug. 16–17, 2024, in Albuquerque and on Oct. 3–4, 2024, in Cleveland. According to the announcement, IBN and CNW will use their comprehensive portfolio of communications tools to optimize virtual coverage, including a minimum of one syndicated article and one newsbreak distributed through IBN’s proprietary network of more than 5,000 strategic partners. IBN will also broadcast live updates featuring the events to its two-plus million social media likes, followers and subscribers. The coverage also includes featured placement of CannaCon events on event pages for both IBN and CNW. “CannaCon West Albuquerque looks forward to helping grow the west’s cannabis industry for years to come and to service business needs across a diverse range of requirements,” said CannaCon director of marketing Angela Grelle in the press release. “We are very pleased to have InvestorBrandNetwork and CannabisNewsWire on board as our media partners for the remainder of 2024. IBN’s world-class communications outreach and services will play a key role in elevating the visibility of our events and garnering greater interest across discrete geographies. We look forward to working side-by-side with their highly professional and dedicated team. This is a must-attend event for anyone interested in the cannabis sector as well as active and curious consumers.”

To view the full press release, visit https://cnw.fm/FOMU1

About CannaCon

CannaCon is a distinctive conference company dedicated to creating and strengthening lifelong partnerships within the emerging cannabis industry to showcase industry products, people, innovations, and technology. Leveraging its history, networks, and deep expertise in the cannabis space, the conference develops and hosts industry-leading events that cultivate business values through education and responsible community involvement in this specialized domain. To learn more about the company, please visit www.CannaCon.org.

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Illinois Cannabis Convention & Expo to Attract the Biggest Traders in the Cannabis Spectrum

The NECANN Illinois Cannabis Convention 7 Expo is being held May 31 – June 1, 2024, at the Schaumburg Convention Center, Chicago, IL. One of the biggest cannabis B2B conventions in the country, the event will witness prominent growers, traders, enthusiasts, patients, educators, dealers, and top industry leaders.

Newcomers as well as seasoned businesses can showcase their products or unique ideas at the exhibitor booths to gain visibility among the top investors, industries, and traders in the cannabis industry. The exhibitor booths significantly attract the crowds as they have fresh and innovative items on display.

Operating since 2014, NECANN events are constantly expanding, offering knowledge, and a robust platform for networking & collaborations, all under one roof. The NECANN events attract a huge number of local businesses and communities of the cannabis industry, providing them with singular growth and business opportunities.

The attendees can create their own personalized schedules, bookmarking those events that they want to attend. Several eminent leaders will be conducting speaker sessions where they will share their invaluable insights and knowledge to design winning marketing strategies in a highly competitive landscape. The discussion panels will discuss new trends and strategies for the cannabis market to help businesses drive higher ROI. Participants can gain know-how about the latest trends in the cannabis industry by attending the many exhibitor booths at the event.

Topics of discussion range from business & growth, cultivation, social equity, tracks, and trends. Investors seeking new avenues for trade need to explore the event as NECANN attracts a large number of vendors from across the country. From enthusiasts to business founders, the NECANN Illinois Convention & Expo has the richest selection of opportunities to offer in the cannabis community.

To know more, please visit https://cnw.fm/RsltI.

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Reports Confirm DEA Is Close to Reclassifying Marijuana

The U.S. Drug Enforcement Administration (DEA) is set to change the classification of cannabis. The proposal, pending review by the White House Office of Management and Budget (OMB), acknowledges marijuana’s medical potential and implies that it is less prone to abuse compared to other certain drugs. However, it does not advocate for the complete legalization of marijuana for recreational purposes.

The move, disclosed by anonymous sources familiar with the matter, signals a major policy change for the DEA and a shift in U.S. drug policy. Once approved, the agency will invite public feedback on moving cannabis from Schedule I to III, aligning it with substances such as certain steroids and ketamine, as recommended by the U.S. Health and Human Services (HHS). Following public commentary and administrative review, a final ruling will be issued.

In a statement, Xochitl Hinojosa, the U.S. Department of Justice (DOJ) director of public affairs, confirmed the circulation of a proposal to reclassify cannabis, emphasizing the formal rulemaking process it would initiate upon publication by the Federal Register.

This development follows President Joseph Biden’s call for a federal cannabis law review in 2022, coupled with efforts to pardon numerous individuals convicted of minor cannabis possession charges. Further, the announcement, strategically timed for an election year, may bolster Biden’s support, especially among younger demographics.

Biden, alongside bipartisan lawmakers, has long since advocated for the DEA’s decision as public acceptance of cannabis grows, as reflected in a recent Gallup poll showing that 70% of American adults support legalization, a stark increase from 2000. Despite reclassification to Schedule III, cannabis would still be regulated and subject to federal laws. Critics argue against altering marijuana’s classification, fearing adverse effects, while proponents advocate for treating it as alcohol is treated.

While many states have moved ahead with cannabis legalization, federal reform has lagged. This has led to the rapid growth of the cannabis industry, estimated to be worth nearly $30 billion. Relaxing federal laws could alleviate the significant tax burden on businesses and facilitate research on marijuana, currently hindered by its Schedule I status. The immediate impact on the justice system might be limited, as federal prosecutions for simple possession are infrequent. However, loosening restrictions could have unintended consequences in the ongoing war on drugs.

Critics also highlight logistical challenges, such as the DEA’s capacity to regulate thousands of dispensaries currently in operation across the country. Additionally, the U.S. international obligations, particularly the 1961 Single Convention on Narcotic Drugs, pose a significant obstacle. Previous attempts to reschedule cannabis, citing international obligations, were denied during the Obama administration.

This anticipated reclassification could open up more opportunities not only for marijuana companies but also ancillary companies, such as Innovative Industrial Properties Inc. (NYSE: IIPR), that serve plant-touching businesses.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Finds Frequent Cannabis Use Doesn’t Cause Paranoia, Lower Motivation

Recent research on the effects of regular marijuana usage disproves popular perceptions about the drug by showing no connection between habitual users’ decreased motivation or paranoia. The study found no indication of a marijuana-induced hangover the following day.

One of the unexpected results was that long-term users did not exhibit a decline in desire or effort-exertion willingness, either due to internal or external factors. In fact, consumers who used the product more frequently claimed to be more motivated and to have experienced more negative emotions and impulsivity.

The study highlights both expected and unexpected results, challenging misconceptions surrounding cannabis’ effects. The researchers attribute much of the misunderstanding to cannabis’ historical criminalization, which has skewed perceptions of the drug and its users. According to the authors, even though cannabis is widely used, especially when compared to tobacco, alcohol and caffeine, little is known about how it affects regular users in daily life.

Reddit served as a source for the study’s participants, who had to be at least 21 years of age and from Canada or the United States. Participants were required to use cannabis at least three times weekly for recreational purposes. Throughout the weeklong study period, participants completed a 30-minute baseline assessment and a brief assessment five times daily between 10 a.m. and 11 p.m.

The study found negligible influence on motivation, defying popular belief. Interestingly, the study indicated that people like to become high. In addition to feeling less stressed and afraid, chronic users reported feeling a variety of good emotions while high, including amazement, inspiration and thankfulness.

Interestingly, and against widespread perceptions, chronic users’ levels of paranoia did not rise when they got high. However, it was associated with decreased momentary conscientiousness, indicating reduced self-control and organization.

Although cannabis intoxication had short-lived effects on chronic users’ emotional states, there was little evidence of a hangover the next day. Additionally, frequent users reported greater negative emotions but also higher motivation compared to less frequent users.

While the study could not conclusively determine causality, it suggested a complex relationship between cannabis use and emotional states. The authors acknowledge limitations in participant selection, noting that the sample may not represent less frequent or novice users. Despite these limitations, the study provides valuable insights into the everyday experiences of habitual cannabis users, challenging misconceptions and paving the way for future research.

Other recent studies have similarly challenged misconceptions about cannabis, including its neurocognitive effects, which were found to be minimal among medical cannabis patients with chronic health conditions. Additionally, marijuana use was associated with a lower likelihood of cognitive decline and improved cognitive functioning in some studies.

Contrary to claims that marijuana causes mental illness, research has shown modest improvements in cognitive functioning and reduced medication usage among teens and young adults at risk of psychosis who use marijuana regularly. Studies have also debunked claims of marijuana causing IQ loss, attributing observed declines in IQ to shared familial factors rather than marijuana use itself.

Overall, while the long-term effects of cannabis use remain uncertain, recent research suggests that many fears surrounding marijuana may be exaggerated, and further investigation is warranted to better understand its impacts.

As more such studies are conducted and clarify what effects cannabis can or cannot have on its medical or recreational users, entities such as Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) that focus on the production of pharmaceutical-grade marijuana products could see interest in their products grow as the therapeutic effects of cannabis become more familiar to the public.

NOTE TO INVESTORS: The latest news and updates relating to Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) are available in the company’s newsroom at https://cnw.fm/SFWJ

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannaCon West Albuquerque to Unite the Southwest Cannabis Industry

Traders, cannabis stakeholders, license holders, physicians, patients, regulatory authorities, entrepreneurs, capital investors, public officials, and enthusiasts, are invited to attend the CannaCon West Albuquerque at the Albuquerque Convention Center on May 17-18, 2024. The event focuses on bringing together all participants in the cannabis industry for two days of intense exploration, interaction, learning, and collaboration.

As Albuquerque is witnessing an evolving cannabis industry, this event provides a phenomenal platform for cannabis veterans and newcomers to build a solid new industry. The CannaCon West Albuquerque is engaged in boosting the West’s cannabis industry. The Albuquerque network consists of like-minded cannabis businesses that stay connected and support each other, paving the way for growth and higher returns.

Influential industry leaders and decision-makers will talk about the latest issues and regulations, trends, innovations, and strategies. They will also answer queries from attendees during discussions and interactive sessions. The CannaCon expo offers a global networking frontier where eminent canna traders and investors visit to discover new and fresh talent and ideas. This event opens up avenues for trade and opportunities for all segments of cannabis industries in the region.

CannaCon is a one-stop shop offering a gamut of services to attendees ranging from retail displays, cultivation supplies, showcasing industry innovations, world-class genetics, business and legal advice, science and technology, finance, marketing, and so on. New and seasoned entrepreneurs and industry leaders will showcase their offerings to ensure visibility among industry experts and professionals.

Attendees can meet and connect with decision-makers, veterans, and investors and grow their network at CannaCon in a fun and conducive environment.

Bookings for exhibitors and speaker sessions are available.

To learn more, please visit https://cnw.fm/nnKt1

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Extend Operational Runway to 2025 Following Warrant Exercise and Issuance

  • Lexaria has entered an agreement wherein an existing accredited investor has exercised all their warrants to purchase shares
  • The company has received $4.7 million from this undertaking, prior to deducting estimated offering expenses
  • Proceeds fully fund Lexaria’s entire planned 2024 GLP-1 R&D program, leaving additional excess capital for general purposes

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its entry into a warrant exercise agreement with an existing accredited investor to exercise in full certain existing warrants initially issued in October 2023 and February 2024. The warrants will be exercised at $0.97 and $2.185 per share, respectively, with the whole undertaking yielding approximately $4.7 million, prior to deducting estimated offering expenses (https://cnw.fm/YbeyA).

Proceeds from this offering will fund the 2024 GLP-1 research program and go into Lexaria’s working capital. Chris Bunka, the company’s CEO, noted that the funds will further extend its operational runway deep into 2025, an integral milestone given its project pipeline, specifically its focus on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year.

“These additional cash proceeds of $4.7 million further extend Lexaria’s operational runway deep into 2025 and allow us to execute our 2024 plans at an aggressive pace,” noted Mr. Bunka.

This announcement closely follows Lexaria’s recent milestone of three additional patents to its portfolio. In April 2024, the company received two newly granted patents in the U.S. and one in Japan. The first two patents fell under the company’s patent family #24: Compositions and Methods for Treating Epilepsy, while the third fell under patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. While the company maintains its standing on the value of its intellectual property and continues to pursue that, its focus for 2024 has been specifically focused on GLP-1 studies.

“Our R&D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations. We are not at this time planning additional 2024 research in antiviral nicotine, or PDE5 sectors. We have solid early-stage data in each of those areas that will allow us to build upon those at the right time,” noted Mr. Bunka (https://cnw.fm/w21gI).

The $4.7 million will be integral in realizing this objective for the company, even as it pushes for patent applications. With this, its management maintains that its hard work will prove itself in 2024, ultimately creating additional shareholder value.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN